Anthony Molloy - 04 Jan 2023 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Chief Lgl & Compliance Officer
Signature
/s/ Kristen Williams, Attorney-in-Fact
Issuer symbol
PCRX
Transactions as of
04 Jan 2023
Net transactions value
-$27,094
Form type
4
Filing time
06 Jan 2023, 18:04:13 UTC
Previous filing
08 Jun 2022
Next filing
07 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Sale $6,177 -158 -0.78% $39.09 19,996 04 Jan 2023 Direct F1, F2
transaction PCRX Common Stock Sale $20,917 -546 -2.7% $38.31 19,450 05 Jan 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
F2 Includes 204 shares of common stock acquired under the issuer's employee stock purchase plan in December 2022.
F3 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.